Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology

Area of Science:

• Oncology
• Drug Development
• Regulatory Science

Background:

• Breakthrough Therapy Designation (BTD) was established by the US Congress and FDA in 2012 to accelerate the development of drugs for serious illnesses like cancer.
• Qualifying for BTD requires demonstrating substantial clinical improvement over existing therapies for a new molecular entity.
• While administrative criteria are public, specific trial designs, endpoints, and thresholds for BTD are not.

Purpose of the Study:

• To review clinical trial designs and key factors contributing to successful Breakthrough Therapy Designation applications in oncology.
• To provide insights for oncology research teams developing clinical trial designs for expedited drug development programs.

Main Methods:

• Literature review of nine oncology new molecular entities that received Breakthrough Therapy Designation.
• Analysis of 10 associated accelerated approval pathways.
• Summary of critical elements in clinical trial design for successful BTD.

Main Results:

• Identified key factors in clinical trial design that led to successful BTD applications.
• Detailed analysis of trial designs and endpoints used in oncology BTD cases.
• Provided a framework for understanding the quantitative therapeutic thresholds involved.

Conclusions:

• Understanding successful BTD trial design elements can help optimize expedited drug development pathways.
• This review offers practical guidance for oncology research teams aiming for BTD.
• The findings can inform the setting of goals for clinical trial design and therapeutic thresholds in future BTD applications.